Yapay Zeka Hızlı Bakış & Çıkarımlar
AI InsightConclusion: Our study showed that patients who used short-acting insulin analogues gained a little weight, patients who used insulin glulisine gained the most weight, and patients who used insulin lispro lost weight.
📌 3 Maddede Bu Makale
Özet
To investigate the effects of short-acting analogue insulins on weight, and to demonstrate the difference between analogues. Materials and methods: Our study included patients who have used only intensive insulin therapy with metformin. Those who took other oral antidiabetics, other insulin derivatives, or different insulin combinations were excluded from the study because of the adverse effects on patients' weights. Results: Our study included 118 patients who used insulin glargine with short-acting analogue insulins, i.e. insulin aspart (38 patients), insulin lispro (28 patients), and insulin glulisine (52 patients). After 3 to 6 months of treatment, significant weight gain was observed in the patients who had used insulin aspart and insulin glulisine (P = 0.008). However, in contrast to expectations, it was found that patients who had used insulin lispro experienced weight loss. Weight change in the patient group that used insulin lispro compared with weight change in the insulin glulisine group was found to be statistically significant (P = 0.034). Conclusion: Our study showed that patients who used short-acting insulin analogues gained a little weight, patients who used insulin glulisine gained the most weight, and patients who used insulin lispro lost weight.
Abstract
To investigate the effects of short-acting analogue insulins on weight, and to demonstrate the difference between analogues. Materials and methods: Our study included patients who have used only intensive insulin therapy with metformin. Those who took other oral antidiabetics, other insulin derivatives, or different insulin combinations were excluded from the study because of the adverse effects on patients' weights. Results: Our study included 118 patients who used insulin glargine with short-acting analogue insulins, i.e. insulin aspart (38 patients), insulin lispro (28 patients), and insulin glulisine (52 patients). After 3 to 6 months of treatment, significant weight gain was observed in the patients who had used insulin aspart and insulin glulisine (P = 0.008). However, in contrast to expectations, it was found that patients who had used insulin lispro experienced weight loss. Weight change in the patient group that used insulin lispro compared with weight change in the insulin glulisine group was found to be statistically significant (P = 0.034). Conclusion: Our study showed that patients who used short-acting insulin analogues gained a little weight, patients who used insulin glulisine gained the most weight, and patients who used insulin lispro lost weight.